Please login to the form below

Not currently logged in
Email:
Password:

New drugs breathe life into GSK's respiratory business

Revlar/Breo and Anoro offset ongoing Seretide decline with new sales growth
GSK

New drugs for asthma and chronic obstructive pulmonary disease (COPD) grew GlaxoSmithKline's respiratory sales in the second-quarter - for the first time since it lost patent protection for blockbuster Seretide/Advair.

The turnaround in the unit was a key factor in a return to form for GSK, with a second consecutive quarter of growth after a tricky couple of years which has seen generic competition erode around £2bn-worth of Seretide (salmeterol and fluticasone propionate) sales.

New asthma and COPD drugs such as Relvar/Breo (vilanterol/fluticasone furoate) and Anoro (vilanterol/umeclidinium bromide) added £243m ($319m) in the quarter, more than offsetting a 13% decline in Seretide sales to £900m although the respiratory unit as a whole had flat growth.

While US patent protection remains in place - likely until 2017 - there is still a sizeable drop in store for the Seretide/Advair franchise. GSK is hoping that approval of a new triple therapy - currently in late-stage trials - will help it cope with that eventuality.

Outgoing chief executive Sir Andrew Witty said the product's relative importance to the group is “dropping quickly" and - even if there is a big fall-off in the US - "it would hurt in the year [but is] no longer strategic in the sense that it once was".

A firmer respiratory business - coupled with strong growth for HIV drugs through the ViiV Healthcare joint venture which grew 44% to £865m - helped group sales rise 4% to £6.5bn overall. The weak pound - which has plummeted in the wake of the Brexit vote last month - also had a role to play.

GSK's vaccines unit added £960m in the second quarter - up 11% - with the rise driven largely by meningitis vaccine Bexsero, which saw sales more than double to £97m. Consumer health grew 7% to £1.69bn.

Growth was driven by all three divisions - pharmaceuticals, vaccines and consumer health - and put the company on course for earnings growth at the top end of expectations (up 11%-12%).

The results are a boost for Sir Andrew, who had promised a return to earnings growth in 2016 and told investors yesterday that the turnaround was a result of "growth in new product sales, continued cost control and delivery of restructuring and transaction benefits".

He also pointed to the strength of GSK's R&D pipeline, highlighting the new triple therapy for asthma, the recent EU approval for gene therapy Strimvelis, progress with its T-cell therapy for soft tissue sarcoma and first-in-class ICOS agonist 3359609, amongst others.

Article by
Phil Taylor

29th July 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

The gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics